Top Markets
Coin of the day
Instem plc Instem plc

Instem plc

INS
Rank in Stocks #19523
Established in 1969 and based in Stone, United Kingdom, Instem plc provides... Established in 1969 and based in Stone, United Kingdom, Instem plc provides information technology applications to the global life sciences and healthcare sectors. The company's core mission is to equip organizations with robust solutions for data capture, management, and analysis, thereby facilitating informed, data-driven decision-making processes. Instem's extensive suite of offerings addresses diverse needs across research and development. For early-phase clinical trials, it offers ALPHADAS, an eSource system. Discovery research is supported by tools like BioRails for data management and Morphit for data visualization. The portfolio also includes computational toxicology products and services, alongside Provantis, a Windows-based system for non-clinical evaluation studies. Specialized solutions comprise Comet Assay IV, a live video imaging system for reproducible comet slide scoring, and Cyto Study Manager for cytology data acquisition and reporting. Furthermore, NOTOCORD-hem software platforms are available for acquiring, displaying, and analyzing physiological signals. A significant area of focus is regulatory information management. Instem provides Samarind RMS for managing medical product information and a comprehensive set of tools for the Standard for Exchange of Nonclinical Data (SEND). This includes the submit platform for creating and managing SEND datasets, SENDView for reviewing them, SEND Explorer for web-based access with optional data warehousing, and SENDTrial, a subscription-based web solution. Other offerings include Logbook, an information repository, and the Sorcerer Colony Counter for automatic plate counting. Beyond its software products, Instem delivers a broad range of services such as sales support, training, validation, consultancy, and cloud services, in addition to safety assessment and regulatory information management software. The company also develops, manufactures, and supplies both software and hardware specifically for in vitro study data collection and management, enabling intelligence extraction from R&D related healthcare data.
Share Price
$10.38
Last synced: 2023-11-20
Market Cap
$158.81M
Change (1 day)
-7.99%
Change (1 year)
0.00%
Country
GB
Trade Instem plc (INS)

Category

P/E ratio for Instem plc (INS)
P/E ratio as of 2026 TTM: 0
According to Instem plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Instem plc from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.